MoonLake Immunotherapeutics announces landmark Phase 2

MoonLake Immunotherapeutics announces landmark Phase 2 results for Nanobody® sonelokimab in active psoriatic arthritis First placebo-controlled...

Related Keywords

Switzerland ,Moonlake Immunotherapeutics ,Ashley Tapp ,Matthias Bodenstedt ,Mary Jane Elliott ,Namrata Taak ,Patricia Sousa ,Kristian Reich ,Josephf Merola ,Nasdaq ,American College Of Rheumatology ,Ut Southwestern Medical Center ,Exchange Commission ,Health Assessment Questionnaire ,American College ,Jorge Santos ,Chief Executive Officer ,Chief Scientific Officer ,Distinguished Chair ,Medical Center ,Monday November ,Psoriasis Area ,Severity Index ,Health Assessment Questionnaire Disability Index ,Leeds Enthesitis Index ,Patients Assessment ,Hidradenitis Suppurativa Clinical Response ,Global Assessment Score ,Securities Litigation Reform Act ,Annual Report ,Jane Elliott ,Nasdaq Mltx ,Moonlake Immunotherapeutics Ag ,Anobody 174 Sonelokimab ,Jorge Santos Da Silva ,Psoriatic Arthritis ,